CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
Triple-negative breast cancer (TNBC) is known as the most intricate and hard-to-treat subtype of breast cancer. TNBC cells do not express the well-known estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2) expressed by other breast cancer subtypes. This pheno...
Tallennettuna:
| Päätekijät: | , , , , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2022-11-01
|
| Sarja: | Frontiers in Immunology |
| Aiheet: | |
| Linkit: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1018786/full |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|
